U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H16ClN3O
Molecular Weight 313.781
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Amoxapine

SMILES

ClC1=CC2=C(OC3=C(C=CC=C3)N=C2N4CCNCC4)C=C1

InChI

InChIKey=QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2

HIDE SMILES / InChI
Molecular Formula C17H16ClN3O
Molecular Weight 313.781
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.

CNS Activity

Approval Year

1980
62
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Inhibitor
8504
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
AMOXAPINE

Approved Use

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Launch Date

1992
Primary
Approved
8583
AMOXAPINE

Approved Use

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.55 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3997304/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
319 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3997304/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.02 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3997304/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3997304/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Other AEs: Drowsiness, Dry mouth...
Other AEs:
Drowsiness (14%)
Dry mouth (14%)
Constipation (12%)
Blurred vision (7%)
Anxiety (>1)
Insomnia (>1)
Nervousness (>1)
Nightmare (>1)
Restlessness (>1)
Palpitations (>1)
Tremor (>1)
Confusion (>1)
Excitement (>1)
Ataxia (>1)
Edema (>1)
Skin rash (>1)
Prolactin increased (>1)
Nausea (>1)
Dizziness (>1)
Headache (>1)
Fatigue (>1)
Weakness (>1)
Appetite excessive (>1)
Perspiration excessive (>1)
Accommodation disturbance (<1%)
Mydriasis (<1%)
Micturition disorder (<1%)
Urinary retention (<1%)
Nasal stuffiness (<1%)
Hypotension (<1%)
Hypertension (<1%)
Syncope (<1%)
Tachycardia (<1%)
Drug fever (<1%)
Urticaria (<1%)
Photosensitized (<1%)
Pruritus (<1%)
Vasculitis (<1%)
Hepatitis (<1%)
Tingling (<1%)
Tinnitus (<1%)
Disorientation (<1%)
Seizures (<1%)
Hypomania (<1%)
Numbness (<1%)
Incoordination (<1%)
Concentration impairment (<1%)
Hyperthermia (<1%)
Extrapyramidal symptoms (<1%)
Tardive dyskinesia (<1%)
Leukopenia (<1%)
Agranulocytosis (<1%)
Epigastric distress (<1%)
Vomiting (<1%)
Flatulence (<1%)
Abdominal pain (<1%)
Taste peculiar (<1%)
Diarrhea (<1%)
Impotence (<1%)
Menstrual irregularity (<1%)
Breast enlargement (<1%)
Inappropriate antidiuretic hormone secretion (<1%)
Galactorrhea (<1%)
Lacrimation (<1%)
Weight gain (<1%)
Weight loss (<1%)
Impaired liver function (<1%)
Painful ejaculation (<1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Constipation 12%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Drowsiness 14%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Dry mouth 14%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Blurred vision 7%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Abdominal pain <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Accommodation disturbance <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Agranulocytosis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Breast enlargement <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Concentration impairment <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Diarrhea <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Disorientation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Drug fever <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Epigastric distress <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Extrapyramidal symptoms <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Flatulence <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Galactorrhea <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Hepatitis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Hypertension <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Hyperthermia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Hypomania <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Hypotension <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Impaired liver function <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Impotence <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Inappropriate antidiuretic hormone secretion <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Incoordination <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Lacrimation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Leukopenia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Menstrual irregularity <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Micturition disorder <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Mydriasis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Nasal stuffiness <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Numbness <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Painful ejaculation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Photosensitized <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Pruritus <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Seizures <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Syncope <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Tachycardia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Tardive dyskinesia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Taste peculiar <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Tingling <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Tinnitus <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Urinary retention <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Urticaria <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Vasculitis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Vomiting <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Weight gain <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Weight loss <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Anxiety >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Appetite excessive >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Ataxia >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Confusion >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Dizziness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Edema >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Excitement >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Fatigue >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Headache >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Insomnia >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Nausea >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Nervousness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Nightmare >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Palpitations >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Perspiration excessive >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Prolactin increased >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Restlessness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Skin rash >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Tremor >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Weakness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1388
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1388
 likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:2675
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2675
ChemicalBook
CB5375947
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5375947
eMolecules
533809
https://www.emolecules.com/cgi-bin/more?vid=533809
MolPort
MolPort-003-666-768
https://www.molport.com/shop/molecule-link/MolPort-003-666-768
ZINC
ZINC000000000931
http://zinc15.docking.org/substances/ZINC000000000931
PubMed

PubMed

TitleDatePubMed
In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine.
2011-10
Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.
2011
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010-12
Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma.
2010-12
Determination of amoxapine and nortriptyline in blood plasma and serum by salt-assisted liquid-liquid microextraction and high-performance liquid chromatography.
2010-12
Gene expression profile analysis of genes in rat hippocampus from antidepressant treated rats using DNA microarray.
2010-11-30
Tricyclic antidepressants and headaches: systematic review and meta-analysis.
2010-10-20
Refractory hypotension during general anaesthesia caused by the long-term use of amoxapine.
2010-09
Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data.
2010-05-17
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
2010-05
Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report.
2010-04
Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database.
2010-03
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.
2010-02-23
Evaluation and performance of desorption electrospray ionization using a triple quadrupole mass spectrometer for quantitation of pharmaceuticals in plasma.
2010-02
Amoxapine inhibits the delayed rectifier outward K+ current in mouse cortical neurons via cAMP/protein kinase A pathways.
2010-02
Amoxapine-induced tardive dyskinesia.
2010-01-06
Hallucinations: Clinical aspects and management.
2010-01
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes.
2010-01
Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect.
2010-01
A new strategy for antidepressant prescription.
2010
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009-12-02
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009-10-02
Accuracy of Veterans Affairs databases for diagnoses of chronic diseases.
2009-10
Persistence and compliance to antidepressant treatment in patients with depression: a chart review.
2009-06-16
5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials.
2009-06
Depression following thrombotic cardiovascular events in elderly medicare beneficiaries: risk of morbidity and mortality.
2009
Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.
2008-12
Functional expression of the glycine transporter 1 on bullfrog retinal cones.
2008-11-19
Effectiveness of a multifactorial cardiovascular risk reduction clinic for diabetes patients with depression.
2008-10
Determination of tricyclic antidepressants in human plasma using pipette tip solid-phase extraction and gas chromatography-mass spectrometry.
2008-07
An autopsy case of poisoning with ethanol and psychotropic drugs.
2008-04
Amoxapine-associated acute respiratory distress.
2008-01
Effects of different antidepressant treatments on the core of depression.
2008
Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: case reports and review of the literature.
2007-12
Amoxapine as an antipsychotic: comparative study versus haloperidol.
2007-12
Pharmacological causes of hyperprolactinemia.
2007-10
Prevalence and predictors of antidepressant use in a cohort of pregnant women.
2007-09
Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
2007-07-26
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.
2007-05
Differential distribution of glycine transporters in Müller cells and neurons in amphibian retinas.
2005-12-06
The clinical pharmacology of depressive states.
2002-03
The role of substance P in depression: therapeutic implications.
2002-03
A possible mechanism of toxicity by the antidepressant amoxapine based on its effects in three in vitro models.
1989
Biochemical evidence that high concentrations of the antidepressant amoxapine may cause inhibition of mitochondrial electron transport.
1988-03-30
Acute myocardial failure following amoxapine intoxication.
1988-02
Amoxapine-induced cognitive impairment in two patients.
1987-04
Amoxapine-induced extrapyramidal effects.
1986-06
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats.
1985-10
Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine.
1985-10
Amoxapine-associated acute renal failure.
1985-06
Patents

Patents

JP2009526755A
475
JP2011504928A
8
JP2011510954A
147

Sample Use Guides

In Vivo Use Guide
Usual effective dosage is 200 to 300 mg daily. Three weeks constitutes an adequate period of trial providing dosage has reached 300 mg daily (or lower level of tolerance) for at least two weeks. If no response is seen at 300 mg, dosage may be increased, depending upon tolerance, up to 400 mg daily.
Route of Administration: Oral
In Vitro Use Guide
Cells (mouse cortical neurons) were incubated with or without amoxapine varying concentrations of 10, 50, and 100 uM. At a concentration of 10 to 500 uM, amoxapine reversibly inhibited I(K) in a dose-dependent manner and modulated both steady-state activation and inactivation properties.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:28:48 GMT 2025
Edited
by admin
on Mon Mar 31 19:28:48 GMT 2025
Record UNII
R63VQ857OT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Amoxapine
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
ASENDIN
Preferred Name English
AMOXAPINE [USP MONOGRAPH]
Common Name English
AMOXAPINE [VANDF]
Common Name English
2-CHLORO-11-(1-PIPERAZINYL)DIBENZ(B,F)(1,4)OXAZEPINE
Systematic Name English
NSC-759559
Code English
CL-67,772
Code English
DIBENZ(B,F)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-
Systematic Name English
amoxapine [INN]
Common Name English
AMOXAPINE [USP-RS]
Common Name English
CL 67772
Code English
Amoxapine [WHO-DD]
Common Name English
CL 67,772
Code English
AMOXAPINE [MI]
Common Name English
AMOXAPINE [JAN]
Common Name English
LOXAPINE SUCCINATE IMPURITY, AMOXAPINE- [USP IMPURITY]
Common Name English
AMOXAPINE [ORANGE BOOK]
Common Name English
AMOXAPINE [MART.]
Common Name English
AMOXAPINE [USAN]
Common Name English
AMOXAPINE [USP IMPURITY]
Common Name English
CL-67772
Code English
Classification Tree Code System Code
WHO-VATC QN06AA17
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
NDF-RT N0000175752
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
WHO-ATC N06AA17
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
LIVERTOX NBK548520
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
NCI_THESAURUS C94727
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
Code System Code Type Description
DRUG CENTRAL
191
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
EVMPD
SUB05479MIG
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
LACTMED
Amoxapine
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
RXCUI
722
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY RxNorm
FDA UNII
R63VQ857OT
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
CAS
14028-44-5
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
RS_ITEM_NUM
1031401
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
IUPHAR
201
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
MERCK INDEX
m1843
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY Merck Index
CHEBI
2675
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
ECHA (EC/EINECS)
237-867-1
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
INN
3049
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
DRUG BANK
DB00543
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
NSC
759559
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
EPA CompTox
DTXSID7022598
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
WIKIPEDIA
Amoxapine
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
DAILYMED
R63VQ857OT
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
PUBCHEM
2170
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
MESH
D000657
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
ChEMBL
CHEMBL1113
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
SMS_ID
100000087430
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
NCI_THESAURUS
C47397
Created by admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Related Record Type Details
Structure of 8-HYDROXYAMOXAPINE
METABOLITE -> PARENT
Structure of 7-HYDROXYAMOXAPINE
METABOLITE -> PARENT
Structure of LOXAPINE
PARENT -> METABOLITE
Related Record Type Details
Structure of 3-CHLORO-11-(PIPERAZIN-1-YL)DIBENZO(B,F)(1,4)OXAZEPINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-nitroso-amoxapine
IMPURITY -> PARENT
Structure of 1,4-BIS(2-CHLORODIBENZO(B,F)(1,4)OXAZEPINE-11-YL)PIPERAZINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 2-Chlorodibenzo(b,f)-1,4-oxazepin-11-one
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-(2-(4-CHLOROPHENOXY)PHENYL)PIPERAZINE-1-CARBOXAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 2-(4-CHLOROPHENOXY)ANILINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-CARBAMOYL AMOXAPINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CHLOROPHENOXYANILINE CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of Loxapine Succinate
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of Amoxapine
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966